两种分次皮内接种方案与标准剂量接种MVA-BN疫苗的安全性和免疫原性评价
本研究将参与者按1:1:1随机分配,分别接种两剂MVA-BN疫苗(间隔28天):皮内2×10^7 TCID50、皮内1×10^7 TCID50或标准剂量皮下1×10^8 TCID50。第43天,2×10^7皮内方案对标准皮下方案达到非劣效,而1×10^7皮内方案未达到。三种方案血清转化率均高且相似,抗痘苗病毒PRNT半衰期相似,大多数参与者仅出现中度或以下反应原性及轻度非征集性不良事件。
要点
- 第43天,2×10^7皮内方案对标准皮下方案达到非劣效,1×10^7皮内方案未达到。
- 2×10^7皮内方案在第15天和第29天(第二剂前)也非劣效于皮下方案。
- 1×10^7皮内方案在接种后任何时间点均未达到非劣效标准。
核心结论
- 2×10^7皮内方案第43天对皮下方案非劣效,而1×10^7皮内方案未达到非劣效。
- 研究支持在需要时使用2×10^7皮内方案。
研究设计与样本
- 随机1:1:1分配,接种两剂MVA-BN疫苗,间隔28天。
- 分组:皮内2×10^7 TCID50、皮内1×10^7 TCID50、标准剂量皮下1×10^8 TCID50。
- 主要目标:第43天(第二剂后2周)采用痘苗病毒蚀斑减少中和试验(PRNT)几何平均滴度(GMT)比较各皮内方案对标准皮下方案的非劣效性。
主要发现
- 第43天PRNT GMT非劣效性:2×10^7皮内方案达到,1×10^7皮内方案未达到。
- 2×10^7皮内方案在第15天和第29天(第二剂前)也非劣效于皮下方案;1×10^7皮内方案在接种后任何时间点均未达到非劣效标准。
- 三种方案血清转化率均高且相似,抗痘苗病毒PRNT半衰期相似。
- 大多数参与者出现中度或以下注射部位和全身反应原性,仅轻度非征集性不良事件(多为注射部位皮肤变色和结节)。
临床怎么用
- 研究支持在需要时使用2×10^7皮内方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is being used to mitigate disease in the current global mpox outbreak, but a global vaccine shortage may limit large scale vaccination. METHODS: Participants were randomized 1:1:1 to receive two doses of MVA-BN administered 28 days apart: intradermal (ID) 2 × 107 TCID50 (2 × 107 ID), ID 1 × 107 TCID50 (1 × 107 ID), or standard dose subcutaneous (SC) 1 × 108 TCID50 (1 × 108 ID). The primary objective was non-inferiority testing of each ID regimen compared to the standard SC regimen using vaccinia virus plaque reduction neutralizing titer assay (PRNT) geometric mean titers (GMT) at Day 43 (2 weeks post-second vaccination). Secondary objectives were non-inferiority testing of individual peak humoral immune responses, comparison of humoral immune responses, vaccinia virus-specific PRNT half-life (t½), and safety. RESULTS: Day 43 non-inferiority by PRNT GMT was established for the 2 × 107 ID regimen but not the 1 × 107 ID regimen. The 2 × 107 ID regimen was also non-inferior to the SC dose at Days 15 and 29, prior to the second dose; the 1 × 107 ID regimen did not meet the non-inferiority criteria at any point post-vaccination. The three study regimens had similarly high seroconversion rates and similar anti-vaccinia PRNT half-lives. Most participants experienced injection site and systemic reactogenicity of moderate severity or less and only mild unsolicited adverse events (mostly skin discoloration and nodules at the injection site). CONCLUSION: The 2 × 107 ID regimen, but not the 1 × 107 ID regimen, was non-inferior to the SC regimen on Day 43. The study supports use of the 2 × 107 ID regimen if needed. CLINICALTRIALS: govNCT05512949.
引用
- Frey SE, Baden LR, El Sahly HM, et al. Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination. Vaccine. 2025. PMID: 41319397. doi:10.1016/j.vaccine.2025.127959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。